In 2016, the World Health Organization (WHO) set targets to eliminate HCV infection as a public health threat by 2030. The targets include:5

an 80% reduction in HCV infections,

a 65% reduction in HCV-related mortality,

90% of patients with HCV diagnosed, and

80% of patients with HCV treated.

The introduction of well-tolerated, all-oral direct-acting antivirals (DAAs) has the potential to significantly facilitate global elimination efforts, particularly HCV-related mortality and morbidity.4,6,7


While this information is considered to be true and correct at the date of publication (May 2020), changes in circumstances after the time of publication may impact the accuracy of the information.

This page will be updated regularly.


  1. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325–336.
  2. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastro Hepatol 2017;2:161-176.
  3. Hajarizadeh B, et al. Epidemiology and natural history of HCV infection. Nature reviews Gastroenterology & hepatology 2013;10:553-562.
  4. Gane E, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2. Journal of viral hepatitis 2015;22(Suppl 1):46-73.
  5. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. June 2016. Available at: (accessed May 2020)
  6. Wedemeyer H, et al. Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat 2015;22(suppl 1):1–5.
  7. Nahon P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142–56.